Mechanism of Action (MOA) Epidyolex provides a different way to treat seizures vs. conventional anti-epileptic drugs (AEDs):1 Structurally distinct from other AEDs Reduces neuronal hyper-excitability and inflammation through multiple MOAs Does not exert its anticonvulsant effects through interaction with cannabinoid receptors Epidyolex has a novel MOA, providing a valuable new approach to treating seizures. The precise mechanisms by which cannabidiol exerts its anticonvulsant effects in humans are unknown.1 Reduction of neuronal hyper-excitability via 3 main actions (theoretical): 1. GPR55 Image Modulation of intracellular calcium via G-protein coupled receptor 55 (GPR55). 2. TRPV-1 Image Modulation of intracellular calcium via transient receptor potential vanilloid 1 (TRPV-1). 3 ENT-1 Image Modulation of adenosine-mediated signalling through inhibition of adenosine cellular uptake via the equilabrative nucleoside transporter 1 (ENT-1). Discover the results Epidyolex has been assessed in a large, controlled Phase III clinical trial programme within LGS and DS, including 714 patients.1 Efficacy References 1. Epidyolex Summary of Product Characteristics (Date accessed: April 2021).